NEW YORK, January 1, 2026, 07:56 ET — Market closed
Cytokinetics, Incorporated (CYTK.O) shares rose $2.17, or 3.5%, to $63.54 in the last trading session of 2025, after swinging between $60.93 and $64.43 on volume of about 1.85 million shares. U.S. markets were shut on Thursday for the New Year’s Day holiday.
The year-end move keeps focus on the company’s pivot from clinical-stage developer to commercial operator, with investors looking for hard signals on pricing and early demand. For drug developers, the first few weeks of launch execution can reset expectations quickly.
Cytokinetics has said Myqorzo is expected to be available in the United States in the second half of January, and it will be distributed under a REMS (Risk Evaluation and Mitigation Strategy), a safety program that can require certified prescribers and monitoring. The label carries a boxed warning — the FDA’s most serious — for risk of heart failure tied to reduced heart pumping function. The company has also cited regulatory progress in China and Europe, with a European Commission decision expected in the first quarter.
The FDA cleared Myqorzo, also known as aficamten, to treat obstructive hypertrophic cardiomyopathy, a condition in which a thickened heart muscle can block blood flow and cause symptoms. The approval makes it only the second U.S.-cleared cardiac myosin inhibitor, competing with Bristol Myers Squibb’s (BMY.N) Camzyos, and Cytokinetics said it expects pricing in line with Camzyos and will disclose a list price before launch. “Myqorzo seems safer and easier to use compared to Camzyos,” Mizuho analyst Salim Syed said. Reuters
A filing showed Chief Commercial Officer Andrew Callos sold 1,809 Cytokinetics shares on Dec. 29 at $62.44 each, leaving him with 51,353 shares. The form indicated the trade was made under a pre-arranged Rule 10b5-1 plan, which allows insiders to set up trades in advance.
Technicians note the stock is still below a late-December intraday peak of $70.98, with recent trading clustering in the low-to-mid $60s. A move back through the mid-$60s would put that late-December high back on traders’ screens.
With no New Year’s Day session to absorb headlines, traders will be alert to any updates that land into the holiday lull, including pricing details, distribution readiness and reimbursement commentary. Those operational datapoints often move newly commercial biotechs more than incremental trial news.
Cytokinetics has also said it expects topline results in the second quarter of 2026 from ACACIA-HCM, a Phase 3 study of aficamten in adults with non-obstructive hypertrophic cardiomyopathy. That’s a second major checkpoint for investors looking past the initial launch window.
Before the next session, U.S. equities reopen on Friday after the New Year’s Day closure. The first trading day of a new year can bring sizable rebalancing flows that magnify moves in high-beta biotech names.
Macro releases are also on the early-January radar. The Bureau of Labor Statistics calendar shows the Job Openings and Labor Turnover Survey due Jan. 7 and the December employment report scheduled for Jan. 9.
The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28. Changes in the rates outlook can swing valuations for companies whose cash flows are expected further out.
Earnings are the next formal checkpoint. Zacks’ earnings calendar lists Feb. 26 for Cytokinetics’ next quarterly update, though the company has not posted a date.
Related articles: NYSE:BMY
